Drugs / semi-allogeneic human fibroblasts (MRC-5) transfected with DNA
semi-allogeneic human fibroblasts (MRC-5) transfected with DNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00793208 | Dec 2008 → Sep 2010 | non-small cell lung carcinoma | Theresa Whiteside, PhD | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | semi-allogeneic human fibroblasts (MRC-5) transfected with DNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00793208 ↗ |
| Modality | Vaccine | “a new vaccine, consisting of semi-allogeneic fibroblasts transfected with autologous tumor-derived DNA” NCT00793208 ↗ |